SA
Log In
ARVN
OverviewIntelligenceChart

Analyst Sentiment

Wall St. Consensus
Buy
26 analysts·High coverage
68
Score
20 Buy (77%)5 Hold (19%)1 Sell (4%)
Rating Breakdown
Strong Buy
00%
Buy
2077%
Hold
519%
Sell
14%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$10.00
-7.2%
Consensus
$11.00
+2.0%
Bull
$18.00
+67.0%
12-Month Target Range26 analysts
$10.00$11.00$18.00
Current $10.78Consensus
Current Price
$10.78
Upside to Consensus
$0.22

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev-10.65%
EPS—
FY2028
Rev+93.18%
EPS—
FY2029
Rev+29.72%
EPS—

Earnings Surprises

Recent Analyst Actions

Mar 18, 2026Truist Financial
Truist Securities Reiterates Hold Rating on Arvinas Inc. (ARVN) amid positive Parkinson's data
Target:$10.00
-8.8%from $10.96
Feb 24, 2026Wedbush
Arvinas price target raised to $11 from $9 at Wedbush
Target:$11.00
-11.1%from $12.37
Dec 17, 2025Barclays
Arvinas price target raised to $18 from $16 at Barclays
Target:$18.00
+51.3%from $11.90
Oct 30, 2025BTIG
Arvinas Inc. (ARVN) PT Raised to $14 at BTIG
Target:$14.00
+46.0%from $9.59
Oct 15, 2025Goldman Sachs
Arvinas downgraded to Sell from Neutral at Goldman Sachs
Target:$6.00
-36.2%from $9.41
Oct 7, 2025Piper Sandler
Arvinas price target raised to $16 from $14 at Piper Sandler
Target:$16.00
+71.0%from $9.36
Sep 18, 2025BTIG
Arvinas price target lowered to $10 from $16 at BTIG
Target:$10.00
+26.3%from $7.92
Sep 18, 2025Stephens
Arvinas price target lowered to $14 from $16 at Stephens
Target:$14.00
+80.6%from $7.75
Sep 16, 2025Barclays
Arvinas assumed with an Overweight at Barclays
Target:$16.00
+109.4%from $7.64
Jun 2, 2025H.C. Wainwright
Arvinas-Pfizer partnership dynamics may shift, says H.C. Wainwright
Target:$24.00
+227.4%from $7.33
May 5, 2025Truist Financial
Arvinas downgraded to Hold from Buy at Truist
Target:$11.00
+44.2%from $7.63
May 2, 2025BTIG
Arvinas price target lowered to $16 from $69 at BTIG
Target:$16.00
+107.3%from $7.72
Mar 13, 2025Morgan Stanley
Arvinas price target lowered to $12 from $48 at Morgan Stanley
Target:$12.00
+40.4%from $8.55
Mar 12, 2025BMO Capital
Arvinas price target lowered to $20 from $82 at BMO Capital
Target:$20.00
+137.2%from $8.43
Mar 12, 2025Wells Fargo
Arvinas price target lowered to $26 from $60 at Wells Fargo
Target:$26.00
+213.3%from $8.30
Dec 10, 2024BTIG
Arvinas initiated with a Buy at BTIG
Target:$69.00
+180.6%from $24.59
Nov 19, 2024Leerink Partners
Arvinas Inc. (ARVN) PT Lowered to $62 at Leerink Partners
Target:$62.00
+148.6%from $24.94
Oct 31, 2024Oppenheimer
Arvinas Inc. (ARVN) PT Lowered to $40 at Oppenheimer
Target:$40.00
+44.6%from $27.66
Oct 21, 2024Stifel Nicolaus
Stifel Reiterates Buy Rating on Arvinas Inc. (ARVN)
Target:$63.00
+132.4%from $27.11
May 16, 2024Oppenheimer
Oppenheimer Reiterates Outperform Rating on Arvinas Inc. (ARVN)
Target:$70.00
+118.0%from $32.11
Apr 12, 2024H.C. Wainwright
Arvinas Inc. (ARVN) PT Lowered to $87 at H.C. Wainwright on Novartis deal
Target:$87.00
+133.5%from $37.26
Apr 11, 2024Stifel Nicolaus
Arvinas Inc. (ARVN) PT Raised to $72 at Stifel, 'strong case to increase ARV-766 sales estimates'
Target:$72.00
+85.9%from $38.73
Dec 19, 2023Wells Fargo
Wells Fargo Upgrades Arvinas Inc. (ARVN) to Overweight, 'risk/reward is highly favorable'
Target:$63.00
+66.4%from $37.87
Oct 23, 2023Wedbush
Wedbush Upgrades Arvinas Inc. (ARVN) to Outperform
Target:$24.00
+61.8%from $14.83
Jan 3, 2023Wells Fargo
Wells Fargo Downgrades Arvinas to Equal-Weight, Lowers Price Target to $49
Target:$49.00
+43.2%from $34.21

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance